Bulletin
Investor Alert

London Markets Close in:

Market Pulse Archives

Jan. 13, 2020, 12:48 p.m. EST

GW Pharmaceutical stock rallies on better-than-expected sales forecast

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    GW Pharmaceuticals PLC ADR (GWPH)

or Cancel Already have a watchlist? Log In

By Wallace Witkowski

GWPH

GW Pharmaceutical PLC /zigman2/quotes/209686240/composite GWPH +0.55% shares rallied Monday after the cannabis-based medicine company forecast better-than-expected sales of its seizure treatment Epidiolex. U.S. shares of GW surged 7.4% to $115.44 in recent activity. The company said it expects fourth-quarter revenue of about $108 million for the fourth quarter and about $309 million for the year. Analysts surveyed by FactSet estimate revenue of $102.4 million for the fourth quarter and $304.6 million for the year, up from a previous estimate of $100.2 million for the quarter and $302.1 million for the year. The company expects Epidiolex sales of about $104 million for the fourth quarter and about $296 million for the full year. "Our fourth quarter and full year results for 2019 reflect an exceptional launch year for Epidiolex," said Justin Gover, GW chief executive, in a statement. "Our goal in 2020 is not only to continue to drive Epidiolex growth but also to leverage our world leadership in cannabinoid science to advance our pipeline."

/zigman2/quotes/209686240/composite
US : U.S.: Nasdaq
$ 99.04
+0.54 +0.55%
Volume: 17,773
Sept. 25, 2020 10:40a
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$3.07 billion
Rev. per Employee
$20,686
loading...

Get news alerts on GW Pharmaceuticals PLC ADR — or create your own.
This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.